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Destruction of the host intestinal epithelium by donor effector T cell populations is a 
hallmark of graft-versus-host disease (GVHD), but the underlying mechanisms remain 
obscure. We demonstrate that CD8
 
 
 
 T cells expressing CD103, an integrin conferring 
specificity for the epithelial ligand E-cadherin, play a critical role in this process. A TCR 
transgenic GVHD model was used to demonstrate that CD103 is selectively expressed by 
host-specific CD8
 
 
 
 T cell effector populations (CD8 effectors) that accumulate in the host 
intestinal epithelium during GVHD. Although host-specific CD8 effectors infiltrated a wide 
range of host compartments, only those infiltrating the intestinal epithelium expressed 
CD103. Host-specific CD8 effectors expressing a TGF-
 
 
 
 dominant negative type II receptor 
were defective in CD103 expression on entry into the intestinal epithelium, which indicates 
local TGF-
 
 
 
 activity as a critical regulating factor. Host-specific CD8 effectors deficient in 
CD103 expression successfully migrated into the host intestinal epithelium but were 
retained at this site much less efficiently than wild-type host-specific CD8 effectors. The 
relevance of these events to GVHD pathogenesis is supported by the finding that CD103-
deficient CD8
 
 
 
 T cells were strikingly defective in transferring intestinal GVHD pathology 
and mortality. Collectively, these data document a pivotal role for TGF-
 
 
 
–dependent CD103 
expression in dictating the gut tropism, and hence the destructive potential, of CD8
 
 
 
 T cells 
during GVHD pathogenesis.
 
Graft-versus-host disease (GVHD) remains the
primary complication of clinical BM transplan-
tation (BMT) and a major impediment to the
widespread application of this important thera-
peutic modality. The hallmark of GVHD is
the infiltration of donor T lymphocytes into
host epithelial compartments (1, 2) of the skin,
intestine, and biliary tract (3). GVHD occurs
when mature T cells contained in bone mar-
row inoculum are transplanted into immuno-
incompetent hosts. Donor T cells directed to
host histocompatibility antigens are activated
in secondary lymphoid organs (4) by encoun-
tering host APCs (3, 5) or donor-derived
APCs which cross-present host alloantigens
(6). The newly generated T effector popula-
tions then migrate to peripheral host organs (7)
and mediate target organ damage.
Intestinal injury is one of the earliest (8)
and most common (9) features of GVHD. T
cell infiltration into the intestinal epithelium is
not only requisite for intestinal pathology during
GVHD (4, 8), but also profoundly affects GVHD
severity and overall mortality (10). Several
lines of evidence point to a key role for CD8
 
 
 
T cell effector populations (CD8 effectors) in
this process. In experimental GVHD models,
host-reactive CD8 effectors are associated with
the most severe forms of intestinal pathology
(11, 12) and predominate at the site of intestinal
injury (2, 8). Analyses of clinical biopsies also
reveal a predominance of CD8
 
 
 
 T cells within
the epithelium at the site of intestinal GVHD
lesions (13). The notion that host-reactive
CD8 effectors play a central role in GVHD
pathogenesis is strongly supported by clinical
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data demonstrating a reduced incidence of GVHD after
BMT when CD8
 
 
 
 T cells are selectively depleted from the
BM inoculum (14), but not when CD4
 
 
 
 T cells are elimi-
nated (15).
It is often tacitly assumed that preferential targeting of
the intestinal epithelium by CD8 effectors during GVHD
reflects a recognition of tissue-specific MHC I–peptide com-
plexes (16). However, recent studies indicate that the gut
tropism of T effector populations is in large part determined
by the pattern of adhesion molecules expressed on the cell
surface (17–19). We previously demonstrated that the T cell
integrin CD103 (also known as CD103/
 
 
 
7) plays a critical
role in targeting epithelial allografts for destruction by CD8
effectors (20). CD103 confers specificity for the ligand
E-cadherin (21, 22), a tissue-restricted molecule selectively
expressed by cells composing epithelial layers (23). E-Cad-
herin is highly expressed by intestinal epithelial cells, which
is relevant to GVHD pathogenesis (24). Moreover, this intes-
tinal milieu is associated with high activity levels of TGF-
 
 
 
(25, 26), a cytokine known to promote CD103 expression
by CD8
 
 
 
 T cells (27–29). Thus, these data raised the possi-
bility that CD103 expression by CD8
 
 
 
 T cells may dictate
the gut-specificity of GVHD pathology.
We used a TCR-transgenic (TCR-Tg) model of GVHD
(30) to directly test the hypothesis that TGF-
 
 
 
–depen-
dent CD103 expression promotes selective destruction of
the intestinal epithelium by host-specific CD8 effectors
(hsCD8eff). We report that CD103 is selectively expressed
by hsCD8eff that infiltrate the intestinal epithelium during
GVHD and, furthermore, that TGF-
 
 
 
 plays a dominant role
in the induction of such an expression. We further demon-
strate that CD103 expression functions to promote the re-
tention of CD8 effectors in the host intestinal epithelium
and that such interactions are central to the development of
GVHD-associated intestinal pathology and mortality. These
findings document a key role for TGF-
 
 
 
–dependent CD103
expression in targeting the host intestinal epithelium for de-
struction by CD8
 
 
 
 T cells during GVHD pathogenesis.
These data provide insight regarding mechanisms of intesti-
nal GVHD pathology and point to novel targets for thera-
peutic intervention in this important clinical problem.
 
RESULTS
Gut-specific expression of CD103 by hsCD8eff
 
The initial goal of this study was to determine whether CD103
is expressed by hsCD8eff that infiltrate host epithelial compart-
ments during GVHD. To accomplish this, lethally irradiated
BALB/c (L
 
d
 
 
 
) mice received 10 
 
 
 
 10
 
6
 
 bone marrow cells
(BMC) and 10 
 
 
 
 10
 
6
 
 spleen cells (SC) from C57BL/6 (B6)
(H-2
 
b
 
) donors plus trace numbers of SC from 2C TCR-Tg
mice (30). Peripheral CD8 cells from 2C mice express a TCR
with specificity for H-2L
 
d
 
 (31), which is readily detected using
an mAb (1B2) directed to the clonotypic 2C TCR (32). Thus,
the use of mAbs from CD8 and 1B2 in multicolor FACS anal-
yses allowed the phenotypic attributes of donor CD8 effectors
targeting host L
 
d
 
 (host-specific CD8
 
 
 
1B2
 
 
 
 cells) to be moni-
tored in vivo during the course of GVHD.
Before transfer, the vast majority of host-specific
CD8
 
 
 
1B2
 
 
 
 cells contained within the inoculum were
CD44
 
 
 
CD11a
 
lo
 
CD62L
 
hi
 
, indicating a naive phenotype (un-
published data). After adoptive transfer into lethally irradiated
recipients, CD8
 
 
 
1B2
 
 
 
 cells infiltrated host lymphoid (spleen
and mesenteric LNs [MLN]) and nonlymphoid (kidney,
liver, and intestine) compartments as early as day 5 after BMT
and were readily detected by day 7 (Fig. 1). All such cells dis-
played an effector phenotype (CD44
 
hi
 
CD11a
 
hi
 
CD62L
 
lo
 
; Fig.
1 and not depicted). The migration of donor effector T cells
into peripheral compartments correlated with the develop-
ment of classic manifestations of GVHD such as diarrhea,
weight loss, wasting, and mortality (mean survival time
[MST] 
 
 
 
 7.5 
 
 
 
 0.3 d, range 
 
 
 
 6–21 d).
Figure 1. hsCD8eff infiltrate diverse host compartments during 
GVHD. Lethally irradiated BALB/c (H-2d) hosts were adoptively transferred 
with 106 SC from 2C TCR-Tg mice in combination with BMC and SC from 
B6 (H-2b) mice. Multicolor flow cytometry of cell suspensions with mAb 
1B2 to the clonotypic 2C TCR (H-2Ld-specific) was used to identify and 
characterize host-specific CD8 1B2  cells. Data shown are dot plots of 
1B2 versus CD8 expression by lymphocyte populations (left) and histo-
grams of CD44 expression by gated CD8 1B2  lymphocytes (right; y axis, 
events) isolated from various host compartments at day 7 after BMT. 
Isotype control staining is represented by shaded histograms. Data are 
representative of six independent experiments. 
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As shown in Fig. 2, a major subset of hsCD8eff that in-
filtrated the host intestinal epithelium during GVHD ex-
pressed CD103, the percentage of which progressively in-
creased over time. Thus, at day 7 after BMT, 8.4 
 
 
 
 0.6%
(
 
n
 
 
 
 
 
 6) of the CD8
 
 
 
1B2
 
 
 
 T cells expressed CD103; this
percentage increased to 31 
 
 
 
 12.7% (
 
n
 
 
 
 
 
 3) by day 10, to
62 
 
 
 
 6.4% (
 
n
 
 
 
 
 
 3) by day 15, and to 71.5 
 
 
 
 5.5% (
 
n
 
 
 
 
 
 2)
by day 21. However, hsCD8eff that infiltrated other host
compartments, including the spleen, kidney, liver, and
MLN, expressed negligible levels of CD103 at all time
points examined (Fig. 2). The mean percentage 
 
 
 
 SE of
CD8
 
 
 
1B2
 
 
 
 T cells in the spleen that expressed CD103 was
0.36 
 
 
 
 0.2%, 1.2 
 
 
 
 0.87%, 2.57 
 
 
 
 1.1%, and 0.8 
 
 
 
 0.2%
at days 7, 10, 14, and 21, respectively (P 
 
 
 
 0.05 for all val-
ues compared with the intestine). In experiments not
shown, nontransgenic CD8 effectors (1B2
 
 
 
CD8
 
 
 
CD44
 
hi
 
cells) that infiltrated the host intestine also selectively ex-
pressed CD103, demonstrating that gut-specific expression
of CD103 is not unique to TCR-Tg CD8 cells. Thus,
these data revealed that CD103 is selectively expressed by
hsCD8eff infiltrating the intestinal epithelium during the
course of GVHD.
 
Gut-specific expression of CD103 by hsCD8eff is dependent 
on TGF-
 
 
 
 activity
 
In vitro studies (28) indicate that the expression of CD103
by CD8 effectors is regulated by active TGF-
 
 
 
, and mice
overexpressing a dominant negative type II receptor muta-
tion targeted to T cells (33) are deficient in CD103 expres-
sion after in vitro activation in the presence of TGF-
 
 
 
 (un-
published data). To determine whether CD103 expression
by gut-infiltrating hsCD8eff is similarly regulated by TGF-
 
 
 
activity, we used 2C TCR-Tg mice expressing a dominant
negative TGF-
 
 
 
 type II receptor (DNR; reference 33).
Thus, the substitution of 2C-DNR cells for wild-type 2C
cells in our model allowed an assessment of the contribution
of TGF-
 
 
 
 signaling to the induction of CD103 expression
by hsCD8eff infiltrating the intestinal epithelium. In these
experiments, lethally irradiated BALB/c recipients were
adoptively transferred with B6 BM and SC, as well as 2C-
DNR cells. Similar to wild-type 2C, 2C-DNR cells mi-
grated into the intestinal epithelium by day 7 after BMT and
displayed an effector phenotype as indicated by up-regula-
tion of CD44 (Fig. 3 A). However, in contrast to their wild-
type counterparts (Fig. 2), 2C-DNR cells that migrated into
Figure 2. Gut-specific expression of CD103 by hsCD8eff during 
GVHD. Lethally irradiated BALB/c (H-2d) hosts were adoptively transferred 
with 106 SC from 2C TCR-Tg mice in combination with BMC and SC from B6 
(H-2b) mice. At the indicated time points, lymphocytes were isolated from 
the various host organs and subjected to four-color flow cytometry as de-
scribed in the legend to Fig. 1. Data shown are histograms of CD103 ex-
pression by gated host-specific CD8 1B2  lymphocytes (y axis, events). Iso-
type control staining is represented by shaded histograms. Data shown are 
representative of two to six independent experiments. Numbers (top) show 
the mean percentage ( SE) of intestinal CD8  T cells that expressed CD103. 
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the intestinal epithelium were completely devoid of CD103
expression (Fig. 3 A).
To directly compare CD103 expression by wild type
with 2C-DNR cells in the same mouse, equal numbers
(0.5 
 
 
 
 10
 
6
 
) of each cell population were transferred together
into lethally irradiated BALB/c recipients. To discriminate be-
tween the two populations of TCR-Tg cells, wild-type 2C
cells expressing the congenic marker Thy1.1 were gener-
ated,  thus allowing the identification of wild-type 2C
(CD8
 
 
 
1B2
 
 
 
Thy1.1
 
 
 
) and 2C-DNR (CD8
 
 
 
1B2
 
 
 
Thy1.1
 
 )
cells using four-color FACS analyses. A progressively increas-
ing subset of wild-type 2C cells infiltrating the intestinal epi-
thelium up-regulated CD103 (Fig. 3 B, top). In contrast,
a notably lower percentage of 2C-DNR cells expressed
CD103 at the same site at all time points examined (Fig. 3 B,
bottom). At day 15 after BMT, the mean percentage (  SE)
of CD103-expressing cells among wild-type 2C was 43.6  
12.4% (n   3) as compared with 22.2   8.7% (n   3) for
2C-DNR cells (P   0.01). Thus, these data support an im-
portant role for TGF-  activity in regulating CD103 expres-
sion by hsCD8eff that infiltrate the host intestinal epithelium.
CD103 expression promotes the retention of hsCD8eff in 
the intestinal epithelium
The known ligand of mouse CD103 is the epithelial cell-spe-
cific ligand, E-cadherin (21), and CD103 is known to pro-
mote adhesion to E-cadherin–expressing cells (34). Thus,
these data suggested that CD103 expression promotes the re-
tention of CD103 CD8  effectors in the host intestinal epi-
thelium during GVHD (Fig. 2). To test this hypothesis, 2C
mice were crossed onto the CD103 /  background, and the
resulting CD103 /  2C effectors were compared with their
wild-type counterparts for the capacity to migrate into the
host intestinal epithelium. In these experiments, equal num-
bers (0.5   106) of wild-type 2C (Thy1.1 1B2 ) cells and
CD103 /  2C (Thy1.1 1B2 ) cells, combined with B6 BM
and SC, were transferred into lethally irradiated BALB/c
hosts (Thy1.2 /Thy1.2 ). Host organs were harvested at
days 6, 12, 21, and 28 after transfer, and the infiltrating lym-
phocytes were subjected to four-color FACS analyses. Before
transfer, CD8  T cells derived from both donor populations
displayed a naive phenotype (unpublished data), but after
transfer both populations rapidly acquired a CD62LloCD11ahi
phenotype characteristic of T effector cells (see Fig. 5, A and
B). Furthermore, wild-type and CD103 /  hsCD8eff se-
creted comparable levels of the effector cytokines TNF- 
(see Fig. 5 C) and IFN-  (see Fig. 5 D).
As shown in Fig. 4 A (top), CD103 /  hsCD8eff com-
posed 22% of the total CD8 T cells infiltrating the host intesti-
nal epithelium at day 6 after transfer. This percentage was
comparable to that of the wild-type hsCD8eff (Fig. 4 A), indi-
cating that CD103 expression is not required for the initial mi-
Figure 3. Gut-specific expression of CD103 by hsCD8eff is depen-
dent on TGF-  activity. (A) Lethally irradiated BALB/c (H-2d) hosts were 
adoptively transferred with 106 SC from either 2C TCR-Tg mice expressing 
2C-DNR in combination with BMC and SC from B6 (H-2b) mice. Recipients 
were killed at day 7 after BMT and lymphocytes infiltrating the intestinal 
epithelium were subjected to a three-color FACS analysis. Data shown are 
histograms of CD44 (left) or CD103 (right) expression by gated host-specific 
CD8 1B2  (y axis, events). (B) Lethally irradiated BALB/c (H-2d) hosts were 
adoptively transferred with an equal mixture (0.5   106) of SC from wild-
type 2C (Thy1.1 ) and 2C-DNR (Thy1.1 ) mice in combination with BMC 
and SC from B6 (H-2b) mice. Lymphocytes infiltrating the intestinal epi-
thelium were isolated at the indicated time points and subjected to a 
three-color FACS analysis. (left) dot plot shows Thy1.1 and 1B2 expression 
by gated CD8  lymphocytes. (right) histograms show the percentage of 
CD103 expression by gated host-specific CD8 1B2  cells of either a wild-
type 2C (top, Thy1.1 1B2  cells) or 2C-DNR (bottom, Thy1.1 1B2  cells) 
origin (y axis, events). Isotype control staining is indicated by shaded his-
tograms. Results are representative of three independent experiments.JEM VOL. 201, May 16, 2005 1651
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gration of hsCD8eff into the intestinal epithelium. However,
the numbers of wild-type hsCD8eff increased dramatically
over time compared with their CD103 /  counterparts at later
time points (i.e., the ratio of wild type/CD103 /  hsCD8eff
increased to 2:1 by day 21 and to 4:1 by day 28). The selective
retention of wild-type versus CD103 /  hsCD8eff was also
manifest in the spleen by day 28 after transfer (Fig. 4 A), but
not in any of the nonlymphoid organs examined including the
kidney, lung, and liver (Fig. 4 B). Experiments in which the
wild-type 2C cells and CD103 /  2C cells were transferred
separately yielded similar results (unpublished data).
The data in Fig. 4 are consistent with a key role for
CD103 in promoting the retention of hsCD8eff within the
intestinal epithelium, but do not exclude the reasonable pos-
sibilities that CD103 expression may promote the prolifera-
tion of hsCD8eff at this site and/or protect such cells from
apoptosis. To address the former possibility, equal numbers
(0.5    106) of wild-type 2C (Thy1.1 1B2 ) cells and
CD103 /  2C (Thy1.1 1B2 ) cells were carboxy-fluores-
cein diacetate succinimidyl ester (CFSE) labeled and trans-
ferred into lethally irradiated BALB/c hosts (Thy1.2 /
Thy1.2 ) in combination with B6 BM and SC. Lympho-
cytes infiltrating the host intestine and spleen were harvested
at days 3 and 6 after BMT and subjected to four-color FACS
analyses. CD8 1B2  were not detectable in the host intes-
tine or spleen at day 3 after transplantation but were abun-
dant in both compartments by day 6 (unpublished data). As
shown in Fig. 5 F, wild-type and CD103 /  hsCD8eff that
infiltrated the host intestinal epithelium demonstrated com-
parable levels of CFSE expression, indicating similar levels of
cell division. It is important to note, however, that the CFSE
dilution observed in this experiment potentially reflects the
homeostatic- and/or alloantigen-driven expansion of CD8
cells occurring in the peripheral environment before the mi-
gration of CD8 cells into the host epithelium.
To determine whether CD103 expression protects
hsCD8eff from apoptosis, lymphocytes infiltrating the intes-
tinal epithelium were stained with Annexin-V, which de-
tects cells in the early stages of apoptosis (35). As shown in
Fig. 5 E, the frequency of CD103 /  hsCD8eff that
bound Annexin-V was comparable with that of wild-type
hsCD8eff, indicating equivalent apoptosis in the two cell
populations. Thus, we find no evidence that CD103 expres-
sion promotes either the expansion or survival of hsCD8eff
within the intestinal epithelium.
CD103 expression promotes destruction of the host 
intestinal epithelium by CD8  T cells
Hosts transferred with wild-type 2C cells experienced more
rapid mortality (MST   7.5   0.3 d, n   4) than those re-
Figure 4. CD103 expression promotes retention of hsCD8eff in the 
host intestinal epithelium. Lethally irradiated BALB/c (H-2d) hosts were 
adoptively transferred with an equal mixture (0.5   106) of SC from wild-
type 2C (Thy1.11) and 2C-CD1032/2 (Thy1.12) mice in combination with 
BMC and SC from B6 (H-2b) mice. Lymphocytes infiltrating host organs 
were isolated at the indicated time points and subjected to a three-color 
FACS analysis. (A) Dot plots of Thy1.1 versus 1B2 expression by gated 
CD81 lymphocytes isolated from the intestinal epithelium (top) or spleen 
(bottom) at the indicated time points. (B) Dot plots of Thy1.1 versus 1B2 
expression by gated CD8  lymphocytes isolated from the indicated organs 
at day 28 after BMT. Numbers in quadrants denote the corresponding 
percentages among gated CD8  T cells.CD103 PROMOTES GUT-SPECIFIC GVHD PATHOLOGY | El-Asady et al. 1652
ceiving CD103 /  2C cells (MST   24.7   5.9 d, n   4)
or 2C-DNR cells (MST   16.3   2.4 d, n   4; unpub-
lished data). These data suggested that CD103 expression by
hsCD8eff is causally related to the development of GVHD
pathology and mortality. However, the interpretation of sur-
vival data in this model was confounded by the presence of
donor CD4  T cells (derived from the initial B6 SC inocu-
lum) which potentially contribute to GVHD pathogenesis
(8). Furthermore, it was not clear that pathology mediated
Figure 5. Properties of wild-type and CD103 /  host-specific CD8 
cells that infiltrate the host intestinal epithelium during GVHD. 
(A–E) Lethally irradiated BALB/c (H-2d) hosts were adoptively transferred 
with an equal mixture (0.5   106) of SC from wild-type 2C (Thy1.1 ) and 
2C-CD103 /  (Thy1.1 ) mice in combination with BMC and SC from B6 
(H-2b) mice. Recipients were killed at the indicated time points and lym-
phocytes infiltrating various host organs were subjected to a three-color 
FACS analysis. Data shown are the expression of CD11a (A), CD62L (B), 
TNF-  (C), IFN-  (D), and Annexin-V (E) by wild-type (left) or CD103 /  
(right) host-specific CD8 cells (gated Thy1.1 1B2  or Thy1.1 1B2  cells, 
respectively) isolated from the intestinal epithelium at day 6. Shaded his-
tograms represent isotype control staining. Results are representative of 
two to three independent experiments. (F) Equal numbers of CFSE-labeled 
splenic T cells from wild-type (Thy1.1 ) and CD103 /  (Thy1.1 ) 2C mice 
were transferred into lethally irradiated BALB/c mice in combination with 
BMC and SC from B6 (H-2b) mice. Lymphocytes were harvested from the 
intestine at day 6 after BMT and analyzed by four-color flow cytometry. 
Data shown are CSFE fluorescence by wild-type (left) or CD103 /  (right) 
host-specific CD8 cells (gated Thy1.1 1B2  or Thy1.1 1B2  cells, respec-
tively) isolated from the intestinal epithelium. Shaded histograms show 
CSFE fluorescence at day 0. Y axis, events.
Figure 6. CD103 expression promotes destruction of the host 
intestinal epithelium by CD8  T cells during GVHD. Lethally irradiated 
BALB/c (H-2d) hosts were adoptively transferred with 10   106 B6 BMC 
alone or in combination with 10   106 CD8-enriched SC from either wild-
type or CD103 /  mice on the B6 (H-2b) background. (A) Survival of recip-
ients of B6 BMC alone (dashed line, n   4), or in combination with CD8  T 
cells from wild-type (dotted line; MST   8.2   0.8 d, n   11) or CD103 /  
(continuous line; MST   48.6   6.5 d, n   10) donors (P   0.001). 
(B) Representative H&E sections of intestinal specimens at day 14 after 
BMT from recipients of wild-type (left) or CD103 /  (right) CD8  T cells, 
at low (top, 20 ) and high (bottom, 40 ) magnification. Arrows denote 
apoptotic bodies. (C) Representative H&E sections of liver specimens at 
day 14 after BMT in recipients of wild-type (left) or CD103 /  (right) CD8  
T cells (magnification, 20 ).JEM VOL. 201, May 16, 2005 1653
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by a clonal population of CD8  T cells directed to a single
MHC–peptide complex would be representative of a normal
(polyclonal) response.
To unambiguously assess the impact of CD103 expres-
sion on GVHD mediated by polyclonal CD8  T cells, two
groups of BALB/c mice were lethally irradiated and adop-
tively transferred with CD8-enriched SC ( 0.5% CD4 con-
tamination) obtained from either wild-type or CD103 / 
donors (polyclonal B6 background) in combination with B6
BM. An additional control group received B6 BMC alone.
Hosts from each group were monitored for survival, and in-
testinal specimens were analyzed histologically. As shown in
Fig. 6 A, recipients of CD103 /  CD8-enriched T cells en-
joyed dramatically prolonged survival times (MST   48.6  
6.5 d, n   10) compared with recipients of wild-type cells
(MST   8.2   0.8 d, n   11; P   0.001). Indeed, recipi-
ents of CD103 /  CD8 cells exhibited mortality kinetics
similar to recipients of BMC alone. Furthermore, as shown
in Fig. 6 B, histopathologic evaluation of intestinal speci-
mens from mice transferred with wild-type cells revealed
more pronounced destruction than that seen in cohorts re-
ceiving CD103 /  cells (e.g., villus atrophy, architectural
distortion, lymphocytic infiltration, and the appearance of
apoptotic bodies). A quantitative analysis of the latter in the
two groups revealed a fourfold increase in the number of ap-
optotic bodies in recipients of wild-type cells compared with
recipients of CD103 /  cells. Analyses of liver pathology re-
vealed a mild to moderate cellular infiltrate in both groups
(Fig. 6 C).
As shown in Fig. 7, FACS analyses of donor-origin lym-
phocytes infiltrating the intestinal epithelium at day 14 after
BMT in recipients of wild-type lymphocytes revealed a vast
predominance of CD8 effectors (80–90% of infiltrating lym-
phocytes),   40% of which expressed CD103. Note that
CD103 expression by gut-infiltrating lymphocytes was al-
most entirely confined to the CD8 subset (Fig. 7). There
was a corresponding twofold decrease in the abundance of
CD103 /  cells in the intestinal epithelium as compared
with wild-type counterparts (unpublished data). Thus, these
data are consistent with a key role for CD103 in promoting
both the retention and pathogenic potential of polyclonal
host-reactive CD8 effectors that infiltrate the host intestinal
epithelium during GVHD.
DISCUSSION
The infiltration and destruction of the host intestinal epithe-
lium by donor T cells is a hallmark of GVHD. Although the
afferent pathways underlying the development of GVHD are
increasingly well defined (3, 36), the critical efferent pathways
by which T effector populations attack and destroy host tis-
sues remain obscure. The present study documents a key role
for CD103 in promoting intestinal GVHD pathology medi-
ated by CD8  T cells. These data provide insight into effer-
ent pathways of GVHD and identify novel targets for thera-
peutic intervention in this important clinical problem.
In our studies, a TCR-Tg GVHD model was used to
monitor the acquisition of CD103 expression by hsCD8eff
during the course of GVHD. These studies revealed that
CD103 is selectively expressed by hsCD8eff that infiltrate
the host intestinal epithelium. Although hsCD8eff populated
diverse host compartments including the spleen, kidney,
liver, and lymph nodes, only those that infiltrated the intesti-
nal epithelium expressed notable levels of CD103 (Fig. 2).
The overall frequency of CD103  hsCD8eff in the intestine
progressively increased with time concomitant with the de-
velopment of classic GVHD pathology at this site.
That a causal relationship exists between CD103 
hsCD8eff and the destruction of the intestinal epithelium
was demonstrated by the results of transfer experiments using
CD8  T cells from CD103 knockout mice. These data re-
vealed that CD103 expression is required for the efficient
transfer of GVHD mortality and intestinal pathology by
CD8  T cells (Fig. 6). This defect did not reflect an inherent
incompetence of CD8 cells from CD103 knockout mice be-
cause CD103 /  hsCD8eff are activated in response to host
alloantigens and traffic to the intestinal epithelium as effi-
Figure 7. Expression of CD103 by polyclonal CD8 effectors infil-
trating the host intestinal epithelium during GVHD. Lethally irradiated 
BALB/c (H-2d) hosts were adoptively transferred with 10   106 B6 BMC 
and 10   106 CD8-enriched SC from either wild-type (right) or CD103 /  
(left) B6 (H-2b) mice. Lymphocytes were isolated from the host intestinal 
epithelium at the indicated times and subjected to four-color FACS analy-
ses using FITC-conjugated mAb to H-2Kb in combination with anti–CD8-
PerCP, anti–CD103-PE, and anti–CD44-APCs. Data shown are dot plots of 
CD103 versus CD8 expression by gated donor (H-2Kb ) lymphocytes infil-
trating the host intestinal epithelium. Donor CD8  T cells were uniformly 
CD44hi, consistent with a CD8 effector phenotype (not depicted). Results 
are representative of two independent experiments. Numbers in quadrants 
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ciently as their wild-type counterparts (Fig. 4 A; and Fig. 5,
A–C). Moreover, recipients of CD103 /  CD8  T cells de-
veloped mild liver pathology similar to cohorts transferred
with wild-type CD8  T cells (Fig. 6 C). These data are con-
sistent with our prior observation that CD8  T cells in
CD103 /  mice mount normal effector responses to alloan-
tigen, traffic normally to peripheral sites of inflammation,
and reject skin allografts with kinetics identical to wild-type
controls (20).
The present data document a dominant role for the cyto-
kine TGF-  in regulating CD103 expression by CD8  T
cells during the course of GVHD. Thus, hsCD8eff express-
ing DNR differentiated to effector status and efficiently mi-
grated into the host epithelium, but were strikingly defective
as compared with wild-type hsCD8eff in the capacity to up-
regulate CD103 (Fig. 3 C). It is unclear whether the residual
CD103 expression observed for CD8 cells expressing the
DNR mutation (Fig. 3 C) reflects an inherent leakiness of
this mutation or, alternatively, that additional factors operate
to control CD103 expression by CD8 effectors during
GVHD. We favor the former possibility because in vitro
studies indicate that residual CD103 expression by DNR
CD8  T cells is completely abrogated by neutralizing anti–
TGF-  mAb (unpublished data). It is conceivable, however,
that the factors operating to control CD103 expression in
vitro are distinct from in vivo factors. Unfortunately, our ef-
forts to use neutralizing anti–TGF-  mAb in vivo resulted in
the accelerated mortality of the mice because of generalized
lymphocytic infiltration probably resulting from the loss of
the systemic immunosuppressive activity of TGF-  required
for appropriate T cell homeostasis (unpublished data).
The source of TGF-  activity that drives CD103 expres-
sion by hsCD8eff during GVHD is unclear. Given the gut-
specific localization of CD103  hsCD8eff (Fig. 2), it is likely
that CD103 expression is controlled by TGF-  activity
present locally in the intestinal milieu. Consistent with this
possibility, intestinal epithelial cells are known to secrete
TGF-  (26, 37); furthermore, local inflammation in the in-
testine is associated with increased levels of intestinal TGF- 
mRNA (38) and protein (25). An important implication of
these data is that blocking local (intestinal) TGF-  may pro-
vide an effective means for therapeutic intervention in the
CD103 pathway. However, the present data do not exclude
the possibility that CD8 effectors encounter TGF-  activity
and are induced to express CD103 before entry into the in-
testinal epithelium, but are present in extra-intestinal com-
partments at levels below the limits of detection for FACS-
based assay systems.
Our finding that CD103 expression is required for the
efficient accumulation of hsCD8eff in the host intestinal epi-
thelium provides a plausible mechanistic basis for the strik-
ing CD103 dependence of GVHD gut pathology. Thus,
hsCD8eff that were unable to express CD103 (CD103 / 
background) successfully migrated into the host intestinal
epithelium but were retained there less efficiently than wild-
type counterparts (Fig. 4 A). These data are consistent with
the findings of Teshima et al. (39), who recently demon-
strated that intestinal GVHD pathology mediated by CD8 
T cells requires, at least in part, recognition of MHC–pep-
tide complex expressed within the target epithelium. Given
that CD103 recognizes E-cadherin, which is selectively ex-
pressed E-cadherin within the intestinal epithelium (24), the
simplest explanation for these data is that CD103 functions
to promote the adhesion of hsCD8eff in the gut epithelium.
Consistent with this possibility, CD103 is known to pro-
mote the adhesion of CD103-expressing intraepithelial lym-
phocytes to mucosal epithelial cells (34).
Theoretically, the deficient accumulation of CD103 / 
hsCD8eff in the gut epithelium could also reflect a role for
CD103 in promoting the intraepithelial expansion of CD8
effectors or, conversely, in conferring the resistance of such
cells to apoptotic events. However, recent studies indicate
that the engagement of CD103 does not notably promote T
cell proliferation in vitro (unpublished data) and the data de-
picted here (Fig. 5 F) demonstrate that the expansion of
CD103 /  hsCD8eff infiltrating the intestine during GVHD
is comparable with that of wild-type hsCD8eff. In addition,
there were no detectable differences in apoptosis between
wild-type and CD103 /  hsCD8eff at this site (Fig. 5 E).
The simplest explanation for these data is that CD103 criti-
cally functions to promote the retention of hsCD8eff within
the intestinal epithelium during GVHD. Precisely how such
retention promotes GVHD pathology and mortality remains
to be determined.
CD8 effectors are associated with a variety of tissue-spe-
cific immune phenomena including not only intestinal
GVHD pathology, but also organ-specific autoimmune dis-
ease (40), differential immunogenicity of organ allografts
(41), and virus-associated immune pathology (42–44). It is
often tacitly assumed that such processes reflect T cell recog-
nition of MHC I–peptide complexes uniquely expressed
within the target tissues. The present data challenge this con-
cept by demonstrating that TGF- –dependent CD103 ex-
pression can be the salient factor limiting intestinal GVHD
pathology. Thus, even though the 2C TCR confers specific-
ity for H-2Ld associated with the p2Ca peptide (45) ex-
pressed in the host intestinal epithelium, CD103 /  CD8 
T cells expressing the 2C TCR did not inflict considerable
intestinal epithelial damage. Furthermore, tissue destruction
mediated by wild-type CD8 effectors expressing the 2C
TCR was confined to the intestinal epithelium (Fig. 6, B
and C) even though H-2Ld/p2Ca is ubiquitously expressed
by all tissue compartments (45, 46).
Based on the present findings, we propose an alternative
model to explain the gut specificity of GVHD pathology.
After migration into the host intestinal epithelium, hsCD8eff
encounter local TGF-  activity and are induced to express
CD103. CD103 expression, in turn, endows CD8 effectors
with the capacity to engage E-cadherin, which is abundantly
expressed by cells composing epithelial compartments (47).JEM VOL. 201, May 16, 2005 1655
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As a consequence, hsCD8eff expressing CD103 are effi-
ciently retained within the intestinal epithelium and accu-
mulate over time, eventually leading to the destruction of
the underlying epithelium. This process apparently is not re-
quired for the destruction of other epithelial compartments
because recipients of CD103 /  cells eventually develop se-
vere alopecia and dermatologic injury (unpublished data), as
well as liver pathology comparable to that of wild-type
counterparts (Fig. 6 C). As discussed above, the gut-specific
induction of CD103 expression can be explained by the
unique capacity of the intestinal epithelium for the local pro-
duction and/or processing of TGF-  (25).
Intraepithelial accumulation of CD8 effectors has the po-
tential to promote selective destruction of the underlying
epithelium either directly by the cytolysis of adjacent epithe-
lial cells or by the recruitment of additional effector popula-
tions via the production of chemokines and/or cytokines
(48–50). However, a recent study indicated that intestinal
GVHD pathology is mediated by noncytolytic mechanisms;
e.g., the targeted disruption of perforin or FasL pathways in
mouse GVHD models does not abrogate intestinal injury
(51). Based on these data, we postulate that host-specific
CD103 CD8  effectors in the gut epithelium act as senti-
nels that recruit other effector populations with pathogenic
potential to the site, i.e., TNF- –producing CD4  T cells
(52) and/or monocytes (53). Consistent with this possibility,
the total number of non-CD8 cells infiltrating the intestine
in mice transferred with wild-type hsCD8eff was increased
compared with that of mice transferred with CD103 / 
hsCD8eff (mean [  106]   SE   0.44   0.14 for recipients
of wild-type cells vs. 0.25   0.06 for recipients of CD103 / 
cells at 2 wk after BMT; n   4).
In summary, our results indicate that TGF-  dependent
CD103 expression plays a pivotal role in promoting destruc-
tion of the host intestinal epithelium by CD8  T cells during
GVHD pathogenesis. With regard to clinical applications, it
will be important to determine whether anti-CD103 anti-
body has the same beneficial effect as the disruption of TGF- 
signaling or CD103 gene expression, and whether such in-
tervention can prevent GVHD pathology without compro-
mising the beneficial graft-versus-leukemia effect (54). It will
also be important to determine whether similar pathways are
operative in other CD8-dependent immune phenomena
characterized by tissue-specific immune pathology, espe-
cially organ-specific autoimmune disorders and the predis-
position of the gut to immune inflammation.
MATERIALS AND METHODS
Mice. 2C TCR-Tg (H-2b) mice (31) that express a TCR with specificity
for an 8-mer peptide (p2Ca) in association with H-2Ld (46) were originally
obtained from Ted Hansen (Washington University School of Medicine,
St. Louis, MO). 2C mice were routinely maintained by backcrossing het-
erozygous 2C males with B6 females and screening the offspring for expres-
sion of the clonotypic 2C TCR by a FACS of peripheral blood using the
1B2 mAb. Mice expressing a DNR (33) and 2C mice bred onto the DNR
background (2C-DNR) were used in some experiments. B6 (H-2b) and
BALB/c (H-2d) mice were purchased from the Jackson Laboratory. 2C
CD103 /  mice were generated by breeding 2C (H-2b) and CD103 /  B6
(H-2b) mice (55), followed by backcrossing the 2C CD103 /  F1 genera-
tion with the CD103 /  parental strain to generate 2C CD103 /  mice, as
identified by surface staining for the TCR transgene and PCR for the ho-
mozygous CD103 /  mutation. Wild-type congenic 2C Thy1.1  mice
were obtained by interbreeding 2C Thy1.2 /Thy1.2  and B6 Thy1.1 /
Thy1.1  animals to generate a 2C Thy1.1 /Thy1.2  F1 generation. All
mice were maintained under specific pathogen-free conditions in the ani-
mal facility at the University of Maryland, Baltimore. All animal studies
were approved by the Institutional Review Board.
Antibodies. 1B2 mAb (anti-clonotypic 2C TCR, mouse IgG1; reference
32) was obtained from hybridoma culture supernatant. Biotinylated rat anti–
mouse IgG1 was purchased from Caltag. Directly conjugated anti–mouse
antibodies used include CD8-FITC, CD8-PerCP, Thy1.1-PerCP, Thy1.2-
PE, CD44-FITC, CD44-PE, CD62L-PE, M290 (anti-CD103)-PE,
CD11a-PE, CD25-PE, IFN- –PE, TNF- –PE, and the species- and iso-
type-matched controls (all purchased from BD Biosciences).
Adoptive transfer and BMC. Lethally irradiated (8 Gy, 137Cs source)
BALB/c (H-2d) mice were reconstituted within 4–6 h by a single 0.5-ml
intravenous inoculum containing 10   106 B6 BMC and 10   106 B6 SC
with either 106 2C SC or 106 2C-DNR cells. In some experiments, equal
numbers (0.5   106) of wild-type Thy1.1  2C and Thy1.1  2C-DNR SC
were mixed together and adoptively transferred in combination with B6
BMC and SC into lethally irradiated BALB/c hosts. For adoptive transfer
experiments to determine the role of CD103 in lymphocyte migration to
the intestine, equal numbers (0.5   106) of wild-type Thy1.1  2C SC and
CD103 /  Thy1.1  2C SC were mixed and adoptively transferred into a
group of lethally irradiated BALB/c hosts. In some experiments, 106 wild-
type or CD103 /  2C cells were separately transferred into lethally irradi-
ated BALB/c mice in combination with B6 BM and SC.
To examine the survival and organ pathology in recipients of CD103-
deficient CD8 cells, two groups of lethally irradiated BALB/c hosts received
10   106 B6 BMC and either 10   106 CD8-enriched B6 SC or 10   106
CD8-enriched B6 CD103 /  SC. In these experiments, donor SC were
enriched for naive CD8  T cells by treatment with an mAb to CD4
(RL172.4), followed by incubation in 1/10 Low-Tox M rabbit comple-
ment (Accurate Chemical and Scientific). The resulting cell suspensions
contained  0.5% CD4  T cells. To ensure that equivalent numbers of
CD8 cells were transferred in different experiments, FACS analysis using
anti-CD8 and TCR- /  was performed on each preparation to assess the
degree of enrichment for CD8  T cells. Additional experiments were per-
formed by transferring 10   106 B6 BMC alone. Mice were randomly
grouped before and after irradiation and were given acidified drinking water
to prevent infection. Control irradiated untreated mice were also included
in each experiment.
Lymphocyte isolation. Lymphocytes infiltrating the intestinal epithelium
during GVHD were isolated as previously described (56) with modifica-
tions. The small intestine was flushed with PBS. After removal of the
Peyer’s patches and fat, the intestine was divided longitudinally and cut into
2-mm sections. The mucosa was scraped and dissociated by mechanical dis-
ruption on a stirring platform for 15 min in RPMI 1640 with 10% FCS and
1 mM dithioerythritol. Tissue debris and cell aggregates were removed by
passage over a glass wool column in RPMI 1640 with 10% FCS. The lym-
phocytes were obtained by centrifugation on Lympholyte-M (Cedarlane
Laboratories Limited), and the cells were suspended in complete medium.
Lymphocytes were isolated from the kidney as previously described
(29). In brief, the kidney was minced, and the resulting fragments were in-
cubated for 30 min in medium containing collagenase (Worthington Bio-
chemical), soybean trypsin inhibitor (Sigma-Aldrich), and DNase (Roche).
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were isolated from the MLN and spleens of recipients by mincing with for-
ceps and passing the resulting cell suspension through nylon mesh with a
100- m pore size. Lung- and liver-infiltrating lymphocytes were harvested
as previously described (57) with modifications. After perfusion with PBS,
liver and lung tissue was minced and incubated with stirring at 37 C for 30
min in medium containing collagenase, soybean trypsin inhibitor, and
DNase. Lymphocytes were isolated by centrifugation on Lympholyte-M.
Lymphocyte populations were washed twice in FACS buffer before anti-
body staining and FACS analyses.
Histology. Host organs were harvested at the designated times, fixed in
10% buffered formalin, and embedded in paraffin. 6- m sections were
stained with hematoxylin and eosin (H&E) and blindly analyzed.
FACS analyses. For three-color FACS analyses, harvested cells were
stained with PerCP-conjugated mAb to CD8b in combination with FITC-
and PE-conjugated mAbs to markers of interest. For four-color FACS anal-
yses, cells were stained with anti–CD8a-FITC and anti–Thy1.1-PerCP in
combination with PE- and APC-conjugated antibodies. Species and iso-
type-matched mAbs of irrelevant specificity were used as controls for non-
specific fluorescence. After staining, cells were fixed with 0.5% paraformal-
dehyde and analyzed using a FACSCalibur (Becton Dickinson).
For intracellular cytokine staining, harvested cells were activated with
PMA and ionomycin, followed by the addition of 4  l/ml monensin (Golgi
Stop; BD Biosciences) for an additional 6 h at 37 C. Cells were washed and
resuspended in staining buffer followed by surface staining. Cells were then
washed and resuspended in Cytoperm/Cytofix solution (BD Biosciences)
for 20 min on ice and subsequently incubated on ice for 30–60 min with
appropriate dilutions of anti-cytokine or isotype control antibodies. For An-
nexin-V staining, lymphocytes were stained in FACS buffer at 4 C with
FITC-conjugated mAb to CD8b and APC-conjugated mAb to Thy1.1.
Cells were then washed and incubated in Annexin-V binding buffer with
PE/Annexin-V at 1:20 dilution and 7-amino-actinomycin D (to exclude
nonviable cells) for 15 min at room temperature. The cells were washed, re-
suspended in Annexin-V binding buffer, and analyzed within 1 h.
Lymphocyte populations were gated by forward scatter/side scatter
analysis to exclude monocytes and debris. WinMDI 2.8 software (http://
facs.scripps.edu/software.html) was used for the analysis and graphic display
of flow cytometry data. The percentage of positive cells for a given marker
was based on cutoff points chosen to exclude  99% of the negative control
population.
Statistical analyses. Data are expressed as mean   SEM. To assess statisti-
cal significance, Student’s t tests were performed using SigmaPlot 2000 soft-
ware (SPSS Inc.). P   0.05 was considered statistically significant.
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